CareDx Raises Full-Year Revenue Forecast to $500M After Strong Q2 Results
CareDx reported a 52% year‑over‑year increase in second‑quarter revenue to $132 million, driven by higher demand for its transplant‑patient monitoring tests. Adjusted net income more than tripled to $20 million, or $0.37 per share, well above analysts’ expectations. The company lifted its full‑year revenue outlook to $490‑$500 million, up from $447‑$465 million, and raised its EBITDA guidance to $66‑$78 million, up from $43‑$57 million. The Centers for Medicare & Medicaid Services affirmed coverage for CareDx’s kidney, heart and lung transplant surveillance testing. CareDx also completed its acquisition of oncology diagnostics provider Naveris, which management said will accelerate growth.
CEO John Hanna said the results reflect “continued demand across transplant programs, favorable reimbursement dynamics, and increases in testing activity across both surveillance and for‑cause settings.”
Entities: Australia · Canada · CareDx, Inc. · Castle Biosciences · Centers for Medicare & Medicaid Services · Chris Hill · Civeo Corporation · Core Laboratories · Derek Maetzold · John Hanna · Larry Bruno · Naveris
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] Core Laboratories reported Q2 2026 revenue of $124.6 million, up more than 2% from the prior quarter and down 4% year over year. (Core Laboratories Q2 Earnings Call Highlights)
- [○ 1 SOURCE] Core Laboratories' service revenue for Q2 2026 was $94.3 million, flat sequentially and down 2% year over year. (Core Laboratories Q2 Earnings Call Highlights)
- [○ 1 SOURCE] Castle Biosciences posted an adjusted loss per share of $0.07 for Q2 2026, better than the consensus estimate of $0.44 loss per share. (Castle Biosciences (NASDAQ:CSTL) Sees Strong Trading Volume After Earnings Beat)
- [○ 1 SOURCE] Castle Biosciences generated $15.2 million of operating cash flow and held $62.1 million in cash at the end of Q2 2026. (Castle Biosciences (NASDAQ:CSTL) Sees Strong Trading Volume After Earnings Beat)
- [○ 1 SOURCE] Civeo posted adjusted EBITDA of $23.8 million for Q2 2026, down 4.8% year over year, and a net loss of $2.5 million. (Civeo (CVEO) Is Growing, but Australia and Start-Up Costs Are Pressuring Margins - Alphastreet)
- [○ 1 SOURCE] Civeo Corporation reported Q2 2026 revenue of $180.0 million, up 11% year over year. (Civeo (CVEO) Is Growing, but Australia and Start-Up Costs Are Pressuring Margins - Alphastreet)
- [○ 1 SOURCE] Castle Biosciences raised its full‑year 2026 revenue outlook to $365‑$375 million. (Castle Biosciences (NASDAQ:CSTL) Sees Strong Trading Volume After Earnings Beat)
- [○ 1 SOURCE] Castle Biosciences reported Q2 2026 revenue of $99.86 million, a 20.1% increase year over year. (Castle Biosciences (NASDAQ:CSTL) Sees Strong Trading Volume After Earnings Beat)
- [● 3 SOURCES] Net loss for the quarter was $2.5 million, or $0.23 per diluted share. (Civeo Q2 earnings release)
- [○ 1 SOURCE] Margin pressure stemmed from softer occupancy in Australia and start‑up costs in Canada. (Civeo management commentary)
- [● 3 SOURCES] Operating cash flow turned positive at $11.6 million. (Civeo Q2 earnings release)
- [● 3 SOURCES] Adjusted EBITDA for the quarter was $23.8 million. (Civeo Q2 earnings release)